[1]李顺乐a,徐 蒙a,李 蓉b,等.肝内胆管癌组织中CircACTN4 mRNA 和THBS1mRNA 的表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2024,39(03):1-7.[doi:10.3969/j.issn.1671-7414.2024.03.001]
　LI Shunlea,XU Menga,LI Rongb,et al.Relationship between the Expression of CircACTN4 mRNA and THBS1mRNA in Intrahepatic Cholangiocarcinoma Tissue with Clinicopathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(03):1-7.[doi:10.3969/j.issn.1671-7414.2024.03.001]
点击复制

肝内胆管癌组织中CircACTN4 mRNA 和THBS1mRNA 的表达与临床病理特征及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
1-7
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Relationship between the Expression of CircACTN4 mRNA and THBS1mRNA in Intrahepatic Cholangiocarcinoma Tissue with Clinicopathological Features and Prognosis
文章编号:
1671-7414（2024）03-001-07
作者:
李顺乐a; 徐 蒙a; 李 蓉b; 赵向菊a; 柴祎超c; 贾 鸾d
（西安交通大学第二附属医院 a. 普通外科；b. 麻醉科；c. 肿瘤科；d. 泌尿外科，西安 710004）
Author(s):
LI Shunlea; XU Menga; LI Rongb; ZHAO Xiangjua; CHAI Yichaoc; JIA Luand
（a.Department of General Surgery; b. Department of Anesthesiology; c. Department of Oncology; d. Department of Urology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China）
关键词:
肝内胆管癌; 环状核糖核酸辅肌动蛋白α4; 血小板凝血酶蛋白1
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.03.001
文献标志码:
A
摘要:
目的 研究肝内胆管癌（intrahepatic cholangiocarcinoma，ICC）中环状核糖核酸辅肌动蛋白α4（CircRNAsActininα4，Circ ACTN4）和血小板凝血酶蛋白1（platelet thrombin protein 1，THBS1）mRNA 表达与临床病理特征和预后的关系，为临床诊治提供参考。方法 回顾性分析2017 年5 月～ 2020 年6 月西安交通大学第二附属医院诊治的84 例ICC患者；采用实时荧光定量PCR 及免疫组织化学检测组织中CircACTN4 mRNA, THBS1 mRNA 和蛋白表达。Pearson 相关分析ICC 癌组织中CircACTN4 mRNA 与THBS1 mRNA 的相关性。Kaplan-Meier 法（Log-rank 检验）比较不同CircACTN4mRNA, THBS1 mRNA 表达ICC 患者预后差异。COX 回归分析ICC 患者预后影响因素。受试者工作特征(ROC) 曲线分析CircACTN4 mRNA，THBS1 mRNA 对ICC 患者死亡预后的评估价值。结果 ICC 癌组织中CircACTN4 mRNA（3.14±0.42）表达高于癌旁组织(0.76±0.25)，差异具有统计学意义（t=44.094，P ＜ 0.001）；ICC 癌组织中THBS1 mRNA（2.82±0.36）和蛋白阳性率（92.86%）均高于癌旁组织（0.81±0.24，7.14%），差异具有统计学意义（t/χ2=42.068，123.429，均P ＜ 0.001）。ICC 癌组织中CircACTN4 mRNA 与THBS1 mRNA 表达呈正相关（r=0.669，P ＜ 0.001）。TNM 分期Ⅲ期、低分化程度及有淋巴结转移ICC 癌组织中CircACTN4 mRNA, THBS1 mRNA 表达高于TNM 分期Ⅰ～Ⅱ期、高中分化程度及无淋巴结转移癌组织，差异具有统计学意义（χ2=7.949，9.164，12.207；23.270，18.625，19.828，均P ＜ 0.001）。CircACTN4 mRNA高表达组、THBS1 mRNA 高表达组三年累积生存率分别低于CircACTN4 mRNA 低表达组（25.00% vs 56.82%）和THBS1mRNA 低表达组（19.51% vs 62.79%），差异具有统计学意义（Log rankχ2=13.601，24.310，均P ＜ 0.001）。CircACTN4mRNA（OR=1.839，95%CI：1.228~2.753）、THBS1 mRNA（OR=1.744，95%CI：1.245~2.443）、淋巴结转移（OR=1.925，95%CI：1.316~2.816）、TNM 分期（OR=1.613，95%CI：1.223~2.126）及肿瘤分化程度（OR=1.510，95%CI：1.205~1.892）是影响ICC 预后的独立因素（均P<0.01）。CircACTN4 mRNA，THBS1 mRNA 联合检测对ICC 患者死亡预后的评估曲线下面积为0.868，大于单项指标检测0.812，0.784，差异具有统计学意义（Z=3.348，3.847，均P ＜ 0.001）。结论 ICC 中CircACTN4 mRNA 和THBS1 mRNA 表达升高，两者与TNM 分期、分化程度及淋巴结转移相关，是新的评估ICC 患者不良预后的肿瘤标志物。
Abstract:
Objective To investigate the expression of circular RNA (Circ RNAS) Actininα4 (ACTN4) and platelet thrombin protein 1 (THBS1) in intrahepatic cholangiocarcinoma (ICC) and their relationship with clinicopathological characteristics and prognosis, and provide reference for clinical diagnosis and treatment. Method A retrospective analysis was conducted on 84 ICC patients diagnosed and treated in the Second Affiliated Hospital of Xian Jiaotong University from May 2017 to June 2020. The expressions of CircACTN4 mRNA, THBS1 mRNA and protein were detected by real-time fluorescent quantitative PCR and immunohistochemistry. Pearson correlation analysis was used to analyze the correlation between CircACTN4 mRNA and THBS1 mRNA in ICC cancer tissue. The prognostic differences of ICC patients with different CircACTN4 mRNA and THBS1 mRNA expressions were compared by the Kaplan-Meier method (log rank test). COX regression analysis was performed to identify prognostic factors in ICC patients. The prognostic value of CircACTN4 mRNA and THBS1 mRNA in evaluating the risk of death in ICC patients was assessed by receiver operating characteristic (ROC) curve analysis. Results The expression of CircACTN4 mRNA in ICC tissues (3.14 ± 0.42) was higher than that in adjacent tissues（0.76 ± 0.25）, with significant difference (t=44.094, P<0.001). The positive rates of THBS1 mRNA (2.82 ± 0.36 ) and protein positive rate (92.86%) in ICC tissues were higher than those in adjacent tissues（0.81 ± 0.24，7.14%），and the differences were statistically significant (t/χ2=42.068, 123.429, all P<0.001). CircACTN4 mRNA was positively correlated with THBS1 mRNA in ICC cancer tissue (r=0.669, P<0.001). The expressions of CircACTN4 mRNA, THBS1 mRNA in ICC cancer tissues with TNM stage III, low differentiation, and lymph node metastasis were higher than those in TNM stage I ～ II, high differentiation, and non-lymph node metastasis cancer tissues，and the differences were statistically significant（χ2=7.949，9.164，12.207；23.270，18.625，19.828，all P ＜ 0.001). The 3-year cumulative survival rates of the high expression group of CircACTN4 mRNA and THBS1 mRNA were lower than those of the low expression group of CircACTN4 mRNA（25.00% vs 56.82%） and THBS1 mRNA（19.51% vs 62.79%）， and the differences were statistically significant (Log rank χ2=13.601, 24.310, all P<0.001). CircACTN4 mRNA (OR=1.839, 95%CI: 1.228~2.753), THBS1 mRNA (OR=1.744, 95%CI: 1.245~2.443), lymph node metastasis (OR=1.925, 95%CI: 1.316~2.816), TNM staging (OR=1.613, 95%CI: 1.223~2.126), and tumor differentiation (OR=1.510, 95%CI: 1.205~1.892) were independent factors affecting the prognosis of ICC. The area under the curve of the combination detection of circACTN4 and THBS1 mRNA on the prognosis of death in patients with ICC was 0.868, which was greater than that of the single index (0.812 and 0.784), with significant differences (Z=3.348, 3.847, all P<0.001). Conclusion The expressions of CircACTN4 mRNA and THBS1 mRNA were increased in ICC, and they were associated with TNM stage, differentiation, and lymph node metastasis. These markers may serve as novel indicators to evaluate the poor prognosis of ICC patients.

参考文献/References:

[1] MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma:An overview of the current and future therapeutic landscape for clinicians[J]. CA-A Cancer Journal for Clinicians, 2023, 73(2): 198-222.
[2] 毛俊, 沈秀芬, 马润, 等. 基于TCGA 和GEO 数据库建立了肝内胆管癌的预后风险模型及验证分析[J]. 现代检验医学杂志, 2023, 38(3): 40-46, 64. MAO Jun, SHEN Xiufen, MA Run, et al. Establishment and verification of prognostic risk model of intrahepatic cholangiocarcinoma based on TCGA and GEO database[J]. Journal of Modern Laboratory Medicine,2023, 38(3): 40-46, 64.
[3] XU Yi, LENG Kaiming, YAO Yue, et al. A circular RNA, cholangiocarcinoma-associated circular RNA 1, contributes to cholangiocarcinoma progression,induces angiogenesis, and disrupts vascular endothelial barriers[J]. Hepatology, 2021, 73(4): 1419-1435.
[4] 陈秦俊杰. 环状RNA ACTN4 促进肝内胆管癌进展的机制研究[D]. 上海：中国人民解放军海军军医大学, 2021. CHEN Qinjunjie. CircRNA ACTN4 facilitates the progression of intrahepatic cholangiocarcinoma and its molecular mechanisms [D]. Shanghai: PLA Naval Medical University, 2021.
[5] WANG Xiaosong, XING Lei, YANG Rui, et al. The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC[J].Molecular Cancer, 2021, 20(1): 91.
[6] SHEN Jie, CAO Beibei, WANG Yatao, et al. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1):175.
[7] OMATSU M, NAKANISHI Y, IWANE K, et al. THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer[J]. Nature Communications, 2023,14(1): 5534.
[8] 朱兴书, 陈鹏飞, 张萌帆, 等. 125I 腔内照射联合仑伐替尼治疗进展期肝外胆管癌的效果和安全性分析[J]. 临床肝胆病杂志, 2023, 39(10): 2406-2412. ZHU Xingshu, CHEN Pengfei, ZHANG Mengfan, et al. Efficacy and safety of 125I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(10): 2406-2412.
[9] GOETZE T O, BECHSTEIN W O, BANKSTAHL U S, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) -a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/CALGP/ ACO- GAIN-trial [J]. BMC Cancer, 2020,20(1): 122.
[10] DONG Liangqing, LU Dayun, CHEN Ran, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell, 2022, 40(1): 70-87, e15.
[11] 欧小强, 陈俊霞. 环状RNA circACTN4 促进乳腺癌细胞增殖、侵袭和转移的研究[J]. 陆军军医大学学报, 2022, 44(7): 639-647. OU Xiaoqiang, CHEN Junxia. Circular RNA circACTN4 promotes proliferation, invasion and metastasis of breast cancer cells [J]. Journal of Army Medical University, 2022, 44(7): 639-647.
[12] WANG Jinghan, YU Hongming, DONG Wei, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways [J]. Gastroenterology, 2023,164(6): 990-1005.
[13] LIAO Fengchun, LIAO Ziqi, ZHANG Tao, et al. ECFC-derived exosomal THBS1 mediates angiogenesis and osteogenesis in distraction osteogenesis via the PI3K/AKT/ERK pathway[J]. Journal of Orthopaedic Translation, 2022, 37: 12-22.
[14] LIU Xiangyuan, XU Dongsheng, LIU Zhuang, et al. THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition[J].Clinical & Translational Oncology, 2020, 22(10): 1730-1740.
[15] THAMRONGWARANGGOON U, KURIBAYASHI K,ARAKI H, et al. Lactic acidosis induces metabolic and phenotypic reprogramming in cholangiocarcinoma cells via the upregulation of thrombospondin-1[J]. Cancer Science, 2023, 114(4): 1541-1555.
[16] ZHANG Yi, XU Hongwei, CUI Guofei, et al. β-catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma[J].Gastroenterology, 2022, 163(2): 481-494.
[17] KAUR S, BRONSON S M, PAL-NATH D, et al. Functions of thrombospondin-1 in the tumor microenvironment[J]. International Journal of Molecular Sciences, 2021, 22(9): 4570.
[18] CARPINO G, CARDINALE V, DI GIAMBERARDINO A, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma[J]. Journal of Hepatology,2021, 75(6): 1377-1386.
[19] ZHANG Xiuyuan, HUANG Tingting, LI Yiming, et al. Upregulation of THBS1 is related to immunity and chemotherapy resistance in gastric cancer[J].International Journal of General Medicine, 2021, 14:4945-4957.
[20] LEE S M, HAN Y, CHO K H. Deep learning untangles the resistance mechanism of p53 reactivator in lung cancer cells[J]. iScience, 2023, 26(12): 108377.
[21] FU Peiyao, HU Bo, MA Xiaolu, et al. Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis[J]. Carcinogenesis,2020, 41(7): 950-960.
[22] 施学兵, 李炜, 李志臻, 等. 肝内胆管细胞癌淋巴结转移危险因素分析及风险预测[J]. 中华肝胆外科杂志, 2022, 28(5): 333-336. SHI Xuebing, LI Wei, LI Zhizhen, et al. Risk factors in predicting lymph node metastases in intrahepatic cholangiocarcinoma[J]. Chinese Journal of Hepatobiliary Surgery, 2022, 28(5): 333-336.
[23] 李鹏, 齐瑞兆, 余灵祥, 等. 肝内胆管细胞癌切除术后复发与生存时间的影响因素分析[J]. 中华肝胆外科杂志, 2022, 28(4): 270-274. LI Peng, QI Ruizhao, YU Lingxiang, et al. Factors influencing recurrence and survival after resection of intrahepatic cholangiocarcinoma[J]. Chinese Journal of Hepatobiliary Surgery, 2022, 28(4): 270-274.

相似文献/References:

[1]毛 俊,沈秀芬,马 润,等.基于TCGA 和GEO 数据库建立了肝内胆管癌的预后风险模型及验证分析[J].现代检验医学杂志,2023,38(03):40.[doi:10.3969/j.issn.1671-7414.2023.03.008]
　MAO Jun,SHEN Xiu-fen,MA Run,et al.Establishment and Verification of Prognostic Risk Model of Intrahepatic Cholangiocarcinoma Based on TCGA and GEO Database[J].Journal of Modern Laboratory Medicine,2023,38(03):40.[doi:10.3969/j.issn.1671-7414.2023.03.008]

备注/Memo

备注/Memo:
基金项目： 陕西省2021 年重点研发计划（项目编号：2021SF-229）；陕西省2023 年重点研发计划（项目编号：2023-YBSF-386）：2023年陕西省科协青年人才托举计划（项目编号：20230301）。
作者简介：李顺乐（1981-），男，博士，主治医师，研究方向：普通外科，肝胆疾病，E-mail：lishunle4685@126.com。
通讯作者：徐蒙（1991-），男，博士，副研究员，研究方向：普通外科、肝脏病学、肝胆肿瘤，E-mail：Xm19912015@163.com。
更新日期/Last Update: 2024-05-15